Impact of Blueberry Consumption on Gastrointestinal Health
NCT ID: NCT03934177
Last Updated: 2023-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2019-03-26
2023-03-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Blueberry on Gut Microbiota and Metabolic Syndrome
NCT03266055
Effects of Blueberries on Symptoms and Underlying Mechanisms of Functional Gastrointestinal Disorders
NCT04824976
Berries, Inflammation, and Gut Microbiome
NCT04100200
Berries, Bugs, and the Blues
NCT05817383
Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre
NCT05058131
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blueberry powder
4 weeks of supplementation of 24 g whole blueberry powder
Blueberry powder
Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
Placebo powder
4 weeks of supplementation of 24 g placebo powder (maltodextrin)
Placebo powder
A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blueberry powder
Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
Placebo powder
A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* shift workers (shift work overnight (third shift) +/= 3 days/week for the past 3 months)
* 19-70 years of age
Exclusion Criteria
* elevated laboratory values from a comprehensive metabolic panel (CMP) and complete blood count (CBC) with the exception of glucose (+/= 126 mg/dL; if elevated, confirmed with HA1c of greater than or equal to 6.5%) and ALT, AST, or ALP over 2 times normal levels (to allow for mild elevations resulting from fatty liver often seen in obese) unless approved by study physician
* currently pregnant or plans to become pregnant during the study as determined by participant report
* antibiotic use within the last 12 weeks prior to enrollment
* presence of chronic metabolic disease (e.g., cardiovascular disease, diabetes, cancer) or per physician discretion
* recent (past 4 weeks) major change in dietary habits or a plan to have a major change in dietary habits during the study
* habitual blueberry consumption of more than 0.5 cups 2x/week or a 4-week washout period if consumes
* allergy or intolerance to blueberries
* consumption of supplemental fiber, probiotics or prebiotics without an appropriate 4-week washout period
* restrictive dietary patterns (e.g., ketogenic, Paleolithic) or a diet high in fiber (+/= 14 g/1000 kilocalories) to increase study result generalizability to the U.S. population (low-fiber diet), as well as provide another stimuli for gut leakiness
* unwillingness to consent to the study.
19 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rush University Medical Center
OTHER
University of Nebraska
OTHER
University of Nebraska Lincoln
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heather E Rasmussen, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Nebraska Lincoln
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Nebraska
Lincoln, Nebraska, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18557
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.